| Synonyms: | |
| Status: | Phase 2 |
| Entry Type: | Small molecule |
| Molecule Category: | UNKNOWN |
| UNII: | SQC232V4YY |
| InChI Key | MBQYQLWSBRANKQ-IMTBSYHQSA-N |
|---|---|
| Smile | |
| InChI |
|
| Property Name | Value |
|---|---|
| Molecular Formula | C10H11Cl2N3 |
| Molecular Weight | 244.12 |
| AlogP | 1.8 |
| Hydrogen Bond Acceptor | 3.0 |
| Hydrogen Bond Donor | 1.0 |
| Number of Rotational Bond | 1.0 |
| Polar Surface Area | 28.16 |
| Molecular species | BASE |
| Aromatic Rings | 1.0 |
| Heavy Atoms | 15.0 |
| Targets | EC50(nM) | IC50(nM) | Kd(nM) | Ki(nM) | Inhibition(%) | |
|---|---|---|---|---|---|---|
|
Ion channel
Ligand-gated ion channel
Nicotinic acetylcholine receptor
Nicotinic acetylcholine receptor alpha subunit
|
1445-1500 | - | - | - | - | |
|
Ion channel
Ligand-gated ion channel
Nicotinic acetylcholine receptor
Nicotinic acetylcholine receptor beta subunit
|
1445-1500 | - | - | - | - |
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Neuralgia | 2 | D009437 | ClinicalTrials |
| Attention Deficit Disorder with Hyperactivity | 2 | D001289 | ClinicalTrials |
| Diabetic Neuropathies | 2 | D003929 | ClinicalTrials |
| Diabetic Nephropathies | 2 | D003928 | ClinicalTrials |
| Resources | Reference |
|---|---|
| ChEMBL | CHEMBL238465 |
| DrugBank | DB12527 |
| FDA SRS | SQC232V4YY |
| PubChem | 10131048 |
| SureChEMBL | SCHEMBL650488 |
| ZINC | ZINC000028866069 |